SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

This study tests a combination of two drugs — SHR2554 (an EZH2 inhibitor) and chidamide (an HDAC inhibitor) — for people with T-cell lymphoma, a type of blood cancer that has relapsed or stopped responding to prior treatment. **You may be eligible if...** - You are 18–70 years old with confirmed T-cell lymphoma - Your cancer has relapsed or is refractory to at least one prior treatment - You have not previously received HDAC inhibitors - You are in good overall health (ECOG 0 or 1) with a life expectancy of at least 12 weeks - You have at least one measurable lesion on imaging **You may NOT be eligible if...** - You have cancer spread to the brain or spinal fluid - You received a stem cell transplant in the past 60–90 days - You have active serious infection, significant heart disease, or uncontrolled medical conditions - You had major surgery within 4 weeks of starting the study Talk to your doctor to see if this trial is right for you.